Serzone Class Action Settlement: Confidential Inventory Form Due May 13, 2005

Settlement Covers All Serzone Users Who Did Not "Opt-out" by April 8, 2005 Deadline

All persons in the United States and its territories who were prescribed Serzone — an anti-depressant drug marketed and distributed by Bristol-Myers Squibb Company ("BMS") — between March 15, 1995 and October 1, 2004 are covered by the proposed settlement in a class action lawsuit which is pending in a federal court in West Virginia (In re: Serzone Products Liability Litigation MDL 1477, United States District Court for the Southern District of West Virginia, Charleston Division).

If a person covered by this proposed settlement did not send a letter signed by them to the Serzone Claims Administrator prior to April 8, 2005 stating they wanted to be excluded from this settlement, then there is an important deadline coming up in less than two weeks.

Specifically, in order to participate further in this settlement that person must mail a completed Confidential Inventory Form no later than May 13, 2005 to: Serzone Claims Administrator, P.O. Box 11132 Charleston, WV 25339.

More information, as well as the Inventory Form, can be found on the official settlement web site: www.serzoneclaims.com

If you do not have Internet access, a copy of the Inventory Form can be obtained by calling this toll-free number: 1-800-564-6019.  Furthermore, you should call the Serzone Class Action Administrator at this toll-free number if you need any assistance with, or have questions about, the Inventory Form.

To be clear, if you do not mail this Inventory Form to the Serzone Claims Administrator before May 13, 2005 you will not be allowed to participate in this Serzone settlement.  Because of the significance of this deadline, it is strongly advised that one send the completed Inventory Form by Certified or Registered Mail so there is a record of timely mailing.

  • Read more about the Serzone recall

http://www.druginjurylaw.com/Serzone-information.html

(Posted by: Tom Lamb)

Leave a Reply

Your email address will not be published. Required fields are marked *